Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia

Jiangning Tan, Brent R. Weil, Aaron M. Abarbanell, Yue Wang, Jeremy L. Herrmann, Megan L. Dake, Daniel R. Meldrum

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Mesenchymal stem cell (MSC) infusion may reduce myocardial ischemic injury. TNF-α is a proinflammatory cytokine produced in large quantities during myocardial ischemia that can exert beneficial or detrimental effects on MSC function by binding to a 55-kd receptor (TNFR1) or a 75-kd receptor (TNFR2) on MSCs. We investigated whether genetic modification with ablation of TNFR1 and/or TNFR2 affects MSC-mediated protection against myocardial ischemic injury. The MSCs were harvested from wild-type mice (WT-MSCs) and knockout mice with ablation of TNFR1 and/or TNFR2 (TNFR1KO, TNFR2KO, and TNFR1/R2KO MSCs). After anesthesia was initiated via inhalation of isoflurane, myocardial ischemia was induced in rats via coronary artery ligation. Hearts were then injected with vehicle or MSCs (1 × 10 cells/mL). Myocardial function was assessed 28 days postsurgery with 2-dimensional echocardiograms and isolated heart perfusion. Myocardial tissue was collected for cytokine analysis and infarct measurements. We found that MSC treatment offered significant protection against myocardial ischemia, namely by decreasing infarct size, improving heart function, and decreasing ventricular remodeling compared with vehicle. Compared with WT-MSCs, TNFR1KO MSCs conferred increased cardiac protection, although TNFR2KO and TNFR1/R2KO MSCs conferred less cardiac protection. In addition, treatment with TNFR1KO MSCs was associated with decreased levels of proinflammatory cytokines and an increased level of vascular endothelial growth factor in the myocardium, whereas treatment with TNFR2KO or TNFR1/R2KO MSCs was associated with increased levels of proinflammatory cytokines and a decreased level of vascular endothelial growth factor compared with treatment with WT-MSCs. We conclude that MSC TNFR1 and TNFR2 play important roles in MSC-mediated cardiac protection after myocardial ischemia.

Original languageEnglish
Pages (from-to)236-242
Number of pages7
JournalShock
Volume34
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Receptors, Tumor Necrosis Factor, Type I
Tumor Necrosis Factor Receptors
Mesenchymal Stromal Cells
Receptors, Tumor Necrosis Factor, Type II
Ischemia
Myocardial Ischemia
Cytokines
Vascular Endothelial Growth Factor A
Ventricular Remodeling
Cytoprotection
Isoflurane
Wounds and Injuries
Knockout Mice
Inhalation
Ligation
Coronary Vessels
Myocardium
Anesthesia
Perfusion

Keywords

  • cell therapy
  • cytokines
  • Myocardial infarction
  • receptors
  • TNF-α
  • VEGF

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Tan, J., Weil, B. R., Abarbanell, A. M., Wang, Y., Herrmann, J. L., Dake, M. L., & Meldrum, D. R. (2010). Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. Shock, 34(3), 236-242. https://doi.org/10.1097/SHK.0b013e3181d75ae3

Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. / Tan, Jiangning; Weil, Brent R.; Abarbanell, Aaron M.; Wang, Yue; Herrmann, Jeremy L.; Dake, Megan L.; Meldrum, Daniel R.

In: Shock, Vol. 34, No. 3, 09.2010, p. 236-242.

Research output: Contribution to journalArticle

Tan, J, Weil, BR, Abarbanell, AM, Wang, Y, Herrmann, JL, Dake, ML & Meldrum, DR 2010, 'Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia', Shock, vol. 34, no. 3, pp. 236-242. https://doi.org/10.1097/SHK.0b013e3181d75ae3
Tan, Jiangning ; Weil, Brent R. ; Abarbanell, Aaron M. ; Wang, Yue ; Herrmann, Jeremy L. ; Dake, Megan L. ; Meldrum, Daniel R. / Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. In: Shock. 2010 ; Vol. 34, No. 3. pp. 236-242.
@article{d6c866eec4b1438dbe40070e64e8aa6a,
title = "Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia",
abstract = "Mesenchymal stem cell (MSC) infusion may reduce myocardial ischemic injury. TNF-α is a proinflammatory cytokine produced in large quantities during myocardial ischemia that can exert beneficial or detrimental effects on MSC function by binding to a 55-kd receptor (TNFR1) or a 75-kd receptor (TNFR2) on MSCs. We investigated whether genetic modification with ablation of TNFR1 and/or TNFR2 affects MSC-mediated protection against myocardial ischemic injury. The MSCs were harvested from wild-type mice (WT-MSCs) and knockout mice with ablation of TNFR1 and/or TNFR2 (TNFR1KO, TNFR2KO, and TNFR1/R2KO MSCs). After anesthesia was initiated via inhalation of isoflurane, myocardial ischemia was induced in rats via coronary artery ligation. Hearts were then injected with vehicle or MSCs (1 × 10 cells/mL). Myocardial function was assessed 28 days postsurgery with 2-dimensional echocardiograms and isolated heart perfusion. Myocardial tissue was collected for cytokine analysis and infarct measurements. We found that MSC treatment offered significant protection against myocardial ischemia, namely by decreasing infarct size, improving heart function, and decreasing ventricular remodeling compared with vehicle. Compared with WT-MSCs, TNFR1KO MSCs conferred increased cardiac protection, although TNFR2KO and TNFR1/R2KO MSCs conferred less cardiac protection. In addition, treatment with TNFR1KO MSCs was associated with decreased levels of proinflammatory cytokines and an increased level of vascular endothelial growth factor in the myocardium, whereas treatment with TNFR2KO or TNFR1/R2KO MSCs was associated with increased levels of proinflammatory cytokines and a decreased level of vascular endothelial growth factor compared with treatment with WT-MSCs. We conclude that MSC TNFR1 and TNFR2 play important roles in MSC-mediated cardiac protection after myocardial ischemia.",
keywords = "cell therapy, cytokines, Myocardial infarction, receptors, TNF-α, VEGF",
author = "Jiangning Tan and Weil, {Brent R.} and Abarbanell, {Aaron M.} and Yue Wang and Herrmann, {Jeremy L.} and Dake, {Megan L.} and Meldrum, {Daniel R.}",
year = "2010",
month = "9",
doi = "10.1097/SHK.0b013e3181d75ae3",
language = "English",
volume = "34",
pages = "236--242",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Ablation of TNF-α receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia

AU - Tan, Jiangning

AU - Weil, Brent R.

AU - Abarbanell, Aaron M.

AU - Wang, Yue

AU - Herrmann, Jeremy L.

AU - Dake, Megan L.

AU - Meldrum, Daniel R.

PY - 2010/9

Y1 - 2010/9

N2 - Mesenchymal stem cell (MSC) infusion may reduce myocardial ischemic injury. TNF-α is a proinflammatory cytokine produced in large quantities during myocardial ischemia that can exert beneficial or detrimental effects on MSC function by binding to a 55-kd receptor (TNFR1) or a 75-kd receptor (TNFR2) on MSCs. We investigated whether genetic modification with ablation of TNFR1 and/or TNFR2 affects MSC-mediated protection against myocardial ischemic injury. The MSCs were harvested from wild-type mice (WT-MSCs) and knockout mice with ablation of TNFR1 and/or TNFR2 (TNFR1KO, TNFR2KO, and TNFR1/R2KO MSCs). After anesthesia was initiated via inhalation of isoflurane, myocardial ischemia was induced in rats via coronary artery ligation. Hearts were then injected with vehicle or MSCs (1 × 10 cells/mL). Myocardial function was assessed 28 days postsurgery with 2-dimensional echocardiograms and isolated heart perfusion. Myocardial tissue was collected for cytokine analysis and infarct measurements. We found that MSC treatment offered significant protection against myocardial ischemia, namely by decreasing infarct size, improving heart function, and decreasing ventricular remodeling compared with vehicle. Compared with WT-MSCs, TNFR1KO MSCs conferred increased cardiac protection, although TNFR2KO and TNFR1/R2KO MSCs conferred less cardiac protection. In addition, treatment with TNFR1KO MSCs was associated with decreased levels of proinflammatory cytokines and an increased level of vascular endothelial growth factor in the myocardium, whereas treatment with TNFR2KO or TNFR1/R2KO MSCs was associated with increased levels of proinflammatory cytokines and a decreased level of vascular endothelial growth factor compared with treatment with WT-MSCs. We conclude that MSC TNFR1 and TNFR2 play important roles in MSC-mediated cardiac protection after myocardial ischemia.

AB - Mesenchymal stem cell (MSC) infusion may reduce myocardial ischemic injury. TNF-α is a proinflammatory cytokine produced in large quantities during myocardial ischemia that can exert beneficial or detrimental effects on MSC function by binding to a 55-kd receptor (TNFR1) or a 75-kd receptor (TNFR2) on MSCs. We investigated whether genetic modification with ablation of TNFR1 and/or TNFR2 affects MSC-mediated protection against myocardial ischemic injury. The MSCs were harvested from wild-type mice (WT-MSCs) and knockout mice with ablation of TNFR1 and/or TNFR2 (TNFR1KO, TNFR2KO, and TNFR1/R2KO MSCs). After anesthesia was initiated via inhalation of isoflurane, myocardial ischemia was induced in rats via coronary artery ligation. Hearts were then injected with vehicle or MSCs (1 × 10 cells/mL). Myocardial function was assessed 28 days postsurgery with 2-dimensional echocardiograms and isolated heart perfusion. Myocardial tissue was collected for cytokine analysis and infarct measurements. We found that MSC treatment offered significant protection against myocardial ischemia, namely by decreasing infarct size, improving heart function, and decreasing ventricular remodeling compared with vehicle. Compared with WT-MSCs, TNFR1KO MSCs conferred increased cardiac protection, although TNFR2KO and TNFR1/R2KO MSCs conferred less cardiac protection. In addition, treatment with TNFR1KO MSCs was associated with decreased levels of proinflammatory cytokines and an increased level of vascular endothelial growth factor in the myocardium, whereas treatment with TNFR2KO or TNFR1/R2KO MSCs was associated with increased levels of proinflammatory cytokines and a decreased level of vascular endothelial growth factor compared with treatment with WT-MSCs. We conclude that MSC TNFR1 and TNFR2 play important roles in MSC-mediated cardiac protection after myocardial ischemia.

KW - cell therapy

KW - cytokines

KW - Myocardial infarction

KW - receptors

KW - TNF-α

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=77955948601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955948601&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e3181d75ae3

DO - 10.1097/SHK.0b013e3181d75ae3

M3 - Article

C2 - 20160664

AN - SCOPUS:77955948601

VL - 34

SP - 236

EP - 242

JO - Shock

JF - Shock

SN - 1073-2322

IS - 3

ER -